Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siddhesh A Kamat

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Patient|January 26, 2012
Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional surveySiddhesh A Kamat, Krithika Rajagopalan, Judith J Stephenson, et al.
Journal of Managed Care Pharmacy : JMCP|September 9, 2008
Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured populationSiddhesh A Kamat, Krithika Rajagopalan, Ned Pethick, et al.
Drugs in Context|October 7, 2016
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisChristophe Sapin, Ann Hartry, Siddhesh A Kamat, et al.
Current Drug Safety|June 10, 2014
Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychoticsLeslie Citrome, Stephen Johnston, Anagha Nadkarni, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 28, 2018
Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USAMyrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, et al.
Current Medical Research and Opinion|March 9, 2011
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care populationSiddhesh A Kamat, Michael F Bullano, Chun-Lan Chang, et al.
Journal of Affective Disorders|October 4, 2016
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorderMatthew Sussman, Jeffrey Yu, Siddhesh A Kamat, et al.
Drugs in Context|April 27, 2016
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophreniaMichele Wilson, Benjamin Gutierrez, Steve J Offord, et al.
BMC Psychiatry|February 15, 2017
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medicationsPierre-Michel Llorca, Christophe Lançon, Ann Hartry, et al.
Drugs in Context|April 3, 2015
Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patientsSiddhesh A Kamat, Steve Offord, John Docherty, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Patient|January 26, 2012
Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional surveySiddhesh A Kamat, Krithika Rajagopalan, Judith J Stephenson, et al.
Journal of Managed Care Pharmacy : JMCP|September 9, 2008
Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured populationSiddhesh A Kamat, Krithika Rajagopalan, Ned Pethick, et al.
Drugs in Context|October 7, 2016
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisChristophe Sapin, Ann Hartry, Siddhesh A Kamat, et al.
Current Drug Safety|June 10, 2014
Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychoticsLeslie Citrome, Stephen Johnston, Anagha Nadkarni, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 28, 2018
Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USAMyrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, et al.
Current Medical Research and Opinion|March 9, 2011
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care populationSiddhesh A Kamat, Michael F Bullano, Chun-Lan Chang, et al.
Journal of Affective Disorders|October 4, 2016
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorderMatthew Sussman, Jeffrey Yu, Siddhesh A Kamat, et al.
Drugs in Context|April 27, 2016
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophreniaMichele Wilson, Benjamin Gutierrez, Steve J Offord, et al.
BMC Psychiatry|February 15, 2017
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medicationsPierre-Michel Llorca, Christophe Lançon, Ann Hartry, et al.
Drugs in Context|April 3, 2015
Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patientsSiddhesh A Kamat, Steve Offord, John Docherty, et al.
Pageof 2